autoimmune disease

Immunovant Shares Touch 52-Week High After FDA Green Lights IMVT-1402 Study
Immunovant Shares Touch 52-Week High After FDA Green Lights IMVT-1402 Study
Marketwatch
Immunovant
immunology
IMVT-1402
autoimmune disease
FDA
Flag link:
Here come the PD-1 agonists
Here come the PD-1 agonists
EP Vantage
PD-1 agonists
autoimmune disease
Eli Lilly
rheumatoid arthritis
peresolimab
Flag link:
Magenta agrees to reverse merger with Dianthus after setbacks
Magenta agrees to reverse merger with Dianthus after setbacks
BioPharma Dive
Magenta Therapeutics
M&A
Dianthus Therapeutics
autoimmune disease
Flag link:
Joe Jimenez's Aditum finds fresh twist on old idea, paying $10M for autoimmune BTK inhibitor
Joe Jimenez's Aditum finds fresh twist on old idea, paying $10M for autoimmune BTK inhibitor
Fierce Biotech
venture capital
Joe Jimenez
Aditum Bio
autoimmune disease
Flag link:
Regeneron bets on ‘Treg’ cell therapy with Sonoma deal
Regeneron bets on ‘Treg’ cell therapy with Sonoma deal
BioPharma Dive
Regeneron
Sonoma Biotherapeutics
autoimmune disease
cell therapy
Treg cell therapy
Flag link:
Merck KGaA, spying a major market, pays Aqilion €10M to tackle tough autoimmune target
Merck KGaA, spying a major market, pays Aqilion €10M to tackle tough autoimmune target
Fierce Biotech
Merck KGaA
Aqilion
autoimmune disease
Flag link:
Ex-Shire drug improves outcomes in autoimmune disease, setting Certa on path to phase 3
Ex-Shire drug improves outcomes in autoimmune disease, setting Certa on path to phase 3
Fierce Biotech
Certa Therapeutics
Shire
FT011
autoimmune disease
clinical trials
scleroderma
Flag link:
Amgen extends autoimmune pact with small Michigan biotech
Amgen extends autoimmune pact with small Michigan biotech
Endpoints
Amgen
autoimmune disease
Evoq Therapeutics
Flag link:
AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline
BioSpace
AbbVie
HotSpot Therapeutics
drug discovery
drug development
autoimmune disease
Flag link:
Zenas zips up $118M to launch phase 3 for rare autoimmune disease candidate
Zenas zips up $118M to launch phase 3 for rare autoimmune disease candidate
Fierce Biotech
Zenas BioPharma
Xencor
funding
autoimmune disease
Flag link:
Pfizer tops pharma reputation rankings from autoimmune patients
Pfizer tops pharma reputation rankings from autoimmune patients
Medical Marketing and Media
Pfizer
autoimmune disease
reputation
Flag link:
Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease
Autoimmune drug biotech HI-Bio unveils $120M to root out cellular drivers of disease
MedCity News
Human Immunology Bioscience
autoimmune disease
R&D
MorphoSys
kidney disease
Flag link:
AbbVie sheds autoimmune disease drug in blow to partner Inventiva
AbbVie sheds autoimmune disease drug in blow to partner Inventiva
Pharmaphorum
AbbVie
autoimmune disease
Inventiva
cedirogant
Flag link:
Pfizer, Merck and J&J Back UK Startup Mining the Dark Genome for Autoimmune Therapies
Pfizer, Merck and J&J Back UK Startup Mining the Dark Genome for Autoimmune Therapies
BioSpace
Nucleome Therapeutics
funding
precision medicine
autoimmune diseases
Pfizer
JNJ
Merck KGaA
autoimmune disease
Flag link:
Covalent drugs take the stage — again — in Atlas Venture’s latest startup
Covalent drugs take the stage — again — in Atlas Venture’s latest startup
BioPharma Dive
Matchpoint Therapeutics
Atlas Venture
Access Biotechnology
covalent drugs
autoimmune disease
Flag link:
BMS was first but startup Sudo Bio aims to be best at blocking key autoimmune target
BMS was first but startup Sudo Bio aims to be best at blocking key autoimmune target
MedCity News
Sudo Bioscience
TYK2 inhibitors
autoimmune disease
funding
Bristol Myers Squibb
Flag link:
Gilead completes acquisition of MiroBio in $405m cash deal
Gilead completes acquisition of MiroBio in $405m cash deal
PM Live
Gilead Sciences
M&A
MiroBio
autoimmune disease
Flag link:
‘Treg’ cell therapy: bringing CAR-T to autoimmune disease
‘Treg’ cell therapy: bringing CAR-T to autoimmune disease
BioPharma Dive
Treg cell therapy
autoimmune disease
Kyverna Therapeutics
Quell Therapeutics
Sonoma Biotherapeutics
GentiBio
Abata Therapeutics
Flag link:
Trio of biotechs raise funds to make enzymes and develop drugs for IBS and other autoimmune diseases
Trio of biotechs raise funds to make enzymes and develop drugs for IBS and other autoimmune diseases
Endpoints
Hulli Bio
funding
IBS
Precision Autoimmune Therapeutics
autoimmune disease
Zhiyi Biotech
Flag link:
Chasing AnaptysBio and Lilly, MiroBio rounds up $97M for autoimmune checkpoint agonist clinical trials
Chasing AnaptysBio and Lilly, MiroBio rounds up $97M for autoimmune checkpoint agonist clinical trials
Fierce Biotech
MiroBio
venture capital
autoimmune disease
Eli Lilly
AnaptysBio
Medicxi
OrbiMed
Flag link:

Pages